- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03597035
Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Add-On (MAGMAAddOn)
Patiromer add-on to a mineralocorticoid receptor antagonist (MRA) in patients with Type 2 diabetes mellitus and chronic kidney disease (CKD) will reduce blood pressure and left ventricular (LV) mass to a greater extent compared to patients with MRA alone and favorably affect key secondary hemodynamic and inflammatory variables including atherosclerosis progression.
Atherosclerosis is the leading cause of morbidity and mortality in Type II diabetes. A cell type called the monocyte/macrophage is critical to development and complications of atherosclerosis.
This project will evaluate the effectiveness of a medication called Spironolactone in addition to Patiromer in preventing atherosclerosis in Type II diabetes through its effects on cells such as the monocyte. Spironolactone has been demonstrated to be effective for the treatment of patients after a heart attack and stroke. The investigators will evaluate the impact of Spironolactone in combination with Patiromer in reducing atherosclerosis plaque and additionally evaluate its potential in changing inflammation.
The investigators envision that a strategy of simultaneously probing effect of a drug combined with analysis of mechanisms of action and predictive response will likely provide key information with which to design hard event (heart attack, stroke etc.) based trials.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Male or female patients >= 45 years and able to provide informed consent (females must be either post-menopausal for one year, surgically sterile, or using effective contraception. Oral contraceptives are disallowed.)
- Patients with type II diabetes with HbA1c ≤ 9.0 on stable anti-glycemic regimen that may include oral and/or injectable therapy (GLP-1/Insulin etc.). Changes in dose of glycemic regimen is allowed during the course of the trial if felt to be clinically appropriate.
- Glomerular filtration rate (GFR) <90 and evidence of proteinuria (Urine Albumin/Creatinine Ratio of >30 mg/g or equivalent) in a urine specimen within 12 months OR GFR <60 mg/g regardless of proteinuria
- Patients must be on angiotensin-converting-enzyme inhibitor (ACE) and/or angiotensin-resistance-blocker (ARB) therapy with no planned dose adjustments.
- Hyperkalemia defined as serum K+≥ 5.1 meq/L at visit 0 (screening).
Exclusion Criteria
- Uncontrolled hypertension (Systolic Blood Pressure (SBP)>160 and/or Diastolic Blood Pressure (DBP)>95 mmHg at visit 0 (screening) and SBP >145 mm Hg at visit 2).
- GFR (MDRD) of <20 at visit 0 (screening)
- Hyperkalemia defined as serum K+ <5.1 meq/L at visit 0 (screening).
- LDL cholesterol >150 mg/dL
- Plasma triglycerides > 400 mg/dl
- Contraindications to MRI (metallic implants, severe claustrophobia).
- Acute coronary syndrome, Transient ischemic attack, cardiovascular accident (CVA) or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months.
- Evidence of a secondary form of hypertension.
- Initiation of new therapy with statins, ACE/ARB, antioxidants, calcium channel blockers (CCBs), diuretics, β blockers.
- Type I diabetes mellitus
- Known contraindication, including history of allergy to Spironolactone or Patiromer
- Any surgical or medical condition which might alter pharmacokinetics of drug (e.g. renal transplant, liver failure, liver transplant)
- Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.
- Significant hyponatremia defined as Na <130 meq/L.
- History of prior malignancy including leukemia and lymphoma (but not basal cell skin cancer, cured squamous cell cancer and cured prostate cancer).
- History of any severe, life-threatening disease.
- Any surgical or medical conditions which place the patient at higher risk derived from his/her participation into the study, or likely to prevent patient from complying with requirements.
- History of drug abuse within the last 2 years, noncompliance and unwillingness/inability to consent.
- Pregnant women and nursing mothers
- Class III or IV Congestive Heart Failure
- Primary Hyperaldosteronism
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patiromer Add-On
Single arm experimental study in 50 diabetic patients with chronic kidney disease and hyperkalemia.
|
The study participants will receive concomitant treatment with Veltassa 8.4 grams per day and Spironolactone 25 mg per day or maximum tolerated dose.
If dictated by the potassium level, Veltassa can be increased to 16.8 grams per day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Left Ventricular Mass
Time Frame: Time 0: study baseline, beginning of treatment. Time 1: 12 months follow-up, end of treatment.
|
Change in left ventricular mass from baseline to 12 months.
|
Time 0: study baseline, beginning of treatment. Time 1: 12 months follow-up, end of treatment.
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Sanjay Rajagopalan, MBBS, University Hospitals Cleveland Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Metabolic Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Water-Electrolyte Imbalance
- Atherosclerosis
- Hyperkalemia
- Physiological Effects of Drugs
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Natriuretic Agents
- Diuretics
- Hormone Antagonists
- Mineralocorticoid Receptor Antagonists
- Diuretics, Potassium Sparing
- Spironolactone
Other Study ID Numbers
- 02-17-16
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type2 Diabetes
-
Mathias Ried-LarsenUnknownDiabetes Mellitus, Type 2 | Type 2 Diabetes Mellitus | Type2 Diabetes | Type2 Diabetes MellitusDenmark
-
Johns Hopkins UniversityBeth Israel Deaconess Medical CenterActive, not recruitingHypertension | Diabetes Mellitus, Type 2 | Diabetes | Diabetes type2 | Type 2 Diabetes | Type2 Diabetes | Type II Diabetes | High Blood PressureUnited States
-
Sigrid Therapeutics ABCompletedOverweight | PreDiabetes | Prediabetic State | Type2 Diabetes | Obese | Type2 Diabetes Mellitus | Pre DiabetesFinland, Sweden
-
University of ChicagoCompleted
-
Michigan State UniversityUniversity of Michigan; Claremont Graduate UniversityUnknown
-
University of AlbertaSherwood Park Strathcona County Primary Care Network, AlbertaCompleted
-
Brittany L SmallsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
LMC Diabetes & Endocrinology Ltd.Merck Sharp & Dohme LLC; Syreon CorporationWithdrawnType2 Diabetes
Clinical Trials on Spironolactone
-
Medical University of South CarolinaWithdrawnHidradenitis Suppurativa
-
Medical University of South CarolinaWithdrawn
-
Columbia UniversityCompletedHeart FailureUnited States
-
Asan Medical CenterCompletedHeart FailureKorea, Republic of
-
Yonsei UniversityWithdrawn
-
Instituto Nacional de Ciencias Medicas y Nutricion...TerminatedPatients With Fungic InfectionsMexico
-
Assistance Publique - Hôpitaux de ParisSociété de Dermatologie FrançaiseCompletedCutaneous Atrophy Due to CorticosteroidsFrance
-
State University of New York - Upstate Medical...WithdrawnEnd Stage Renal Disease | Congestive Heart FailureUnited States
-
Hebei Medical UniversityTerminatedHeart Failure, CongestiveChina
-
US Department of Veterans AffairsCompleted